

CONTRACEPTION

INDEX TO VOLUME 17

AUTHOR INDEX

- Adatia, A., 341
Agarwal, N., 267, 455
Alapiessa, U., 19
Almonte, H., 195
Amenomori, Y., 41
Anandalaxmi, P.M., 341
Arimura, A., 61, 283
Åstedt, B., 531
Atienza, M.F., 513
Atterfelt, P., 183
Aznar, R., 153
Ballard, C.A., 383
Bard, D.S., 443
Barros, C., 87
Basu, R., 163
Beck, L.R., 253
Bergquist, C., 537
Bhatnagar, S., 341
Björn-Rasmussen, E., 183
Buhi, W.C., 71
Burkman, R.T., 513
Burton, F.G., 221
Bustos-Obregón, E., 87
Chandra, V.L., 341
Chantler, E.N., 35
Chatterjee, A., 163, 407, 547
Ciaccio, L.A., 231
Croxatto, H.B., 553
Das, R.P., 413
Daunter, B., 27, 35
Dericks-Tan, J.S.E., 79
Devi, P.K., 375
Driskell, J.A., 499
Duenhoelter, J.H., 51
Dumbaugh, V.S., 71
Duncan, G.W., 221
Duncan, L.J.P., 291
Eberlein, L., 79
Elstein, M., 35
Erkkola, R., 580
Forte, K., 383
Fotherby, K., 365
Fujimoto, S., 41
Gaitan, J.R., 195
Gallegos, A.J., 153
Ganguly, M., 1
Goel, V., 341
González, J., 87
Gordon, N.R., 221
Goyal, V., 375
Gresser, J.D., 253
Guizer, E., 153
Gullberg, B., 563
Gupta, M., 407
Gupta, T., 547
Hagbard, L., 355
Hamberger, L., 183
Haspels, A.A., 141
Heald, P.J., 329
Hemphill, P., 465
Hernandez, A.B., 195
Herrera, E., 87
Hill, J.L., 231
Hingorani, V., 103, 267,
 341, 455
Howe, G.R., 309
Howes, J.F., 253
Hudson, R., 465, 475, 489
Hümpel, M., 207
Hyman, M.J., 309
Ingemanson, C.-A., 355
Ishihama, A., 41
Jagannatha, K.T., 267, 455
Jain, A.K., 267
Jeyaseelan, S., 103
Johansson, E.D.B., 131
Joshi, U.M., 375
Kalkwarf, D.R., 221
Kalla, N.R., 523
Kemp, W.R., 93
Killian, G.J., 93
Kincl, F.A., 231
King, T.M., 513
Kinra, G., 103, 267, 455
Kobayashi, T., 41
Krishna, U., 341

CONTRACEPTION

INDEX TO VOLUME 17

AUTHOR INDEX (CONTINUED)


- Kwon, H.Y., 237
Lähteenmäki, P., 9, 115,
169, 297, 569
Lauersen, N.H., 383
Laumas, K.R., 103, 267, 341
Leong, P., 475
Liedholm, P., 531, 563
Liukko, P., 580
Lobl, T.J., 123
Luukkainen, T., 115,
169, 569
Macdonald, P.C., 51
Mahan, C.S., 71
Mandleker, A., 341
Matsuda, S., 41
Matsuyama, E., 41
Merino, G., 153
Milewich, L., 51
Mishell, D.R., Jr., 315
Moore, D.E., 315
Naik, V.K., 375
Nakanishi, T., 41
Navarro, C.L., 195
Nillius, S.J., 537
Nilsson, C.G., 9, 115, 569
Nilsson, L., 183
Nilsson, S., 131
Notelovitz, M., 443
Nummi, S., 19
Nygren, K.-G., 131
Osser, S., 563
Pedroza, E., 61, 283
Pharriss, B.B., 489
Pommerenke, G., 207
Porteus, S.E., 123
Pulkkinen, P., 423
Purandare, V.N., 341
Puri, C.P., 267
Quijada, S., 553
Rahman, S.A., 267
Ramos, R.S., 51
Ranta, T., 19
Reno, F., 489
Rivera, R., 195
Ross, A., 247
Ross, J.A., 237
Roy, S., 315
Ruiz, R., 195
Sakamoto, S., 41
Saxena, B.N., 365
Schally, A.V., 61, 283
Sciarra, J.J., 435
Sekiba, K., 41
Sen, K., 163
Shimizu, T., 41
Shrimanker, K., 365
Siddiqui, U.A., 329
Singh, B., 523
Sivin, I., 575
Sjöberg, N.-O., 531, 563
Skimens, W.E., 221
Smith, R.P., 247
Sorbe, B., 355
Soza, X., 553
Speck, U., 207
Spellacy, W.N., 71
Spence, M.R., 513
Srivastava, K., 531
Stanczyk, F.Z., 315
Steel, J.M., 291
Streb, C., 79
Sunouchi, S., 41
Suzuki, M., 41
Swisher, D., 475
Takada, M., 41
Takkar, D., 103, 341
Tangney, C.C., 499
Taubert, H.-D., 79
Tillson, S.A., 465, 475, 489
Valles, J., 195
van den Bergh, A.S., 141
Veal, J.T., 221
Vihko, R., 19
Viinikka, L., 19

CONTRACEPTION

INDEX TO VOLUME 17

AUTHOR INDEX (CONTINUED)

- | | |
|-----------------------------|----------------------|
| Vilchez-Martinez, J.A., 61, | Wendt, H., 207 |
| 283 | WHO, 395 |
| Virker, K.D., 341 | Wide, L., 537 |
| Virkkunen, P., 19 | Wiqvist, N., 183 |
| Wagatsuma, T., 41 | Wise, D.L., 253 |
| Wan, L.S., 1 | Yadav, H.S., 341 |
| Watson, J., 329 | Yanagimachi, R., 413 |
| Weiss, C., 207 | Ylikorkala, O., 19 |
| Weiss, G., 1 | Zatuchni, G.I., 435 |



CONTRACEPTION

INDEX TO VOLUME 17

SUBJECT INDEX

- Abortifacient effectiveness, single 15-me-PGF_{2α} methyl ester vaginal suppository, 383
Abortion, urea amnioinfusion, bacteriologic culture results, 513
Antifertility activity, 5-thio-D-glucose, male (mouse, rat), 123
Antifertility efficacy, PMSG (rat), 547
Assay of long-acting contraceptive steroid formulations (rabbit), 365
Autonomic drugs, vaginally deposited, influence on fertility (rabbit), 309
Bacteriologic culture, effect of midtrimester urea abortion, 513
Birth control, use of stimulatory LH-RH analogue, 537
Bleeding control, norethisterone-releasing IUD, 115
Bleeding pattern,
 comparative clinical evaluation of injectable NET-OEN and DMPA, 395
 d-norgestrel silastic capsules, 315
Bromocriptine, effect upon pituitary stimulation by LH-RH and TRH, 79
Cervical mucus,
 effect of norethisterone, 35
 levels of disulphide and sulphydryl groups, 35
 scanning electronmicroscopy, 27
 sialic acid levels, 27
 trace metal content, 35
α-hlorhydrin,
 effect on glycosidase activity in epididymal epithelial cells (rat), 93
 effect on male fertility (hamster), 413
 effect on phospholipid analysis in testis-epididymis complex (rat), 523
Clinical evaluation, single silastic implant-D containing norethindrone acetate, 341
Clinical experience with FD-1 IUD, 41
Clinical study, single 15(S)15-methyl-PGF_{2α} methyl ester vaginal suppository, 267
Combined oral contraceptive pill, serious complications in insulin-dependent diabetics, 291
Comparative clinical evaluation, multinational, injectable NET-OEN and DMPA, 395
Complications, oral contraception in insulin-dependent diabetics, 291
Conjugated estrogen, post-ovulatory interceptive, 443

CONTRACEPTION

- Contraceptive effects, progesterone-releasing IUD (rabbit),
 465
Copper beads, intraoviductal, effect on fertility (rabbit),
 553
Copper IUD,
 early postpartum insertion, 355
 menstrual blood loss, 153
 pelvic inflammatory disease, 563
Copper T, immediate post-abortal insertion, 237
Cortisone, reversal of antifertility efficacy of PMSG
 (rat), 547
Cu-7 IUD, sialic acid levels in cervical mucus, 27
Cu-7-Gravigard, early postpartum insertion, 355
Cu-T-200, early postpartum insertion, 355
Dalkon Shield,
 immediate post-abortal insertion, 237
 sialic acid levels in cervical mucus, 27
Danazol (17 α -pregn-4-en-20-yne(2,3-d) isoxazol-17-ol),
 effect on gonadotropin basal levels, male (rat), 61
 effect on gonadotropin secretion after ovariectomy
 (rat), 283
 effect on pituitary responsiveness to LH-RH, male
 (rat), 61
Depot-medroxyprogesterone acetate (DMPA)
Diabetics, insulin-dependent, serious complications of
 oral contraception, 291
Dimethyl polysiloxane (silastic^R)
Disulphide and sulphhydryl groups, cervical mucus, 35
DMPA (depot-medroxyprogesterone acetate)
Early abortion by vaginal PG suppositories, 183
Early postpartum insertion of copper IUD, 355
Early pregnancy interruption, use of silastic device
 containing 15-Me-PGF₂ α , 51
Early pregnancy termination, single dose (15(S)15 methyl
 PGF₂ α methyl ester vaginal suppository, 455
Embryology, progesterone-releasing IUD (rabbit), 489
Endometrial histology, effect of norethindrone acetate
 implant, 103
Endometrium, effect of progesterone-releasing IUD on
 fibrinolytic activity, 531
Epididymal epithelial cells, effect on glycosidase activity
 by α -chlorhydrin (rat), 93
Ergocornine methanesulphonate, blockade of ovulation (rat),
 407
Estradiol, plasma level, effect of U11,100A and U11,555A
 (rat), 329
Estradiol cyclopentylpropionate, luteolytic efficacy
 (rat), 163
Estradiol level, immediate postabortal contraception with
 ethinylestradiol + d-norgestrel, 297
Estradiol pattern, d-norgestrel silastic capsules, 315
Estradiol-17 β level following abortion by 15(S)15-methyl-
 PGF₂ α -methyl ester suppositories, 183

CONTRACEPTION

- Estrogen, conjugated, use as post-ovulatory interceptive, 443
Estrogen and female fertility (rat), 163
Ethinyl estradiol,
 level in human milk and plasma after oral administration, 131
 plasma concentration, immediate postabortal contraception, 9
 radioimmunoassay method in human milk, 131
Ethinyl estradiol + megestrol acetate, level in human milk and plasma, 131
Ethinyl estradiol + norgestrel, pituitary response to LH-RH stimulation, 1
Ethinylestradiol + d-norgestrel,
 elimination of HCG, 169
 immediate postabortal contraception, 9
 microdose, immediate postabortal contraception, 169, 297
 suppression of pituitary and ovarian function, 169
Ethinyl estradiol + dl-norgestrel, post-coital contraception, 247
Evaluation of fertilizing capacity of human spermatozoa, penetration of foreign eggs, 87
Fabrication of vaginal contraceptive devices, progestogen-releasing, 221
FD-1 IUD, clinical experience, 41
Female sterilization reversal, report of workshop, 435
Fertility, influence of vaginally deposited autonomic drugs (rabbit), 309
Fertility inhibition, intraoviductal copper beads, 553
Fertilizing capacity of human spermatozoa, evaluation by penetration of foreign eggs, 87
Fibrinolytic activity of endometrium, effect of progesterone-releasing IUD, 531
First-pass effect, consideration during investigations of levonorgestrel, 207
Foreign egg penetration, evaluation of fertilizing capacity of human spermatozoa, 87
Glycosidase activity, effect of α -chlorhydrin treatment, male (rat), 93
Gonadotropin basal levels, effect of Danazol, male (rat), 61
Gonadotropin level, immediate postabortal contraception with ethinylestradiol + d-norgestrel, 297
Gonadotropin secretion, effect of Danazol after ovariectomy (rat), 283
HCG (human chorionic gonadotropin)
HCG elimination, effect of immediate postabortal contraception with ethinylestradiol + d-norgestrel, 169
HCG elimination in relation to blood loss, 15(S)15-methyl-
 PGF₂ α -methyl ester vaginal suppositories, 183

CONTRACEPTION

- Hematocrit, effect of Lippes IUD, 195
Hemoglobin, effect of Lippes IUD, 195
Hormonal study, single 15(S)15-methyl-PGF_{2α} methyl ester vaginal suppository, 267
Human chorionic gonadotropin (HCG)
Immediate postabortal contraception, microdose ethinyl-estradiol + d-norgestrel, 169, 297
Immediate post-abortal IUD insertion, 237
Immediate postabortal oral contraception, plasma concentrations of ethinylestradiol and d-norgestrel, 9
Implant, norethindrone acetate, endometrial histology and progesterone levels, 103
Indomethacin,
 reversal of antifertility efficacy of PMSG (rat), 547
 reversal of luteolytic efficacy of estradiol cyclopentylpropionate (rat), 163
Inhibition of ovulation, use of stimulatory LH-RH analogue, 537
Injectable, long-acting gestagen formulations, assay (rabbit), 365
Injectable NET-OEN and DMPA, comparative clinical evaluation, 395
Injectable sustained release norethisterone system (baboon), 253
Interceptive, post-ovulatory, use of conjugated estrogen, 443
Interruption of early pregnancy, use of silastic device containing 15-Me-PGF_{2α}, 51
Intraoviductal copper beads, effect on fertility (rabbit), 553
Intrauterine device (IUD),
 copper, 355
 copper T, 153, 237
 Cu-7, 27
 Dalkon Shield, 27, 237
 early postpartum insertion, 355
 FD-1, 41
 immediate post-abortal insertion, 237
 levonorgestrel-releasing, 153
 Lippes, 195
 Lippes loop, 237
 Lippes loop D, 153
 menstrual blood loss, 153
 norethisterone-releasing, 115, 153
 d-norgestrel-releasing, 569
 pelvic inflammatory disease, 563
 plasma prolactin level, 71
 progesterone-releasing, 153, 531
 progesterone-releasing (rabbit), 465, 475, 489
 sialic acid levels in cervical mucus, 27
 TCu 200, 563
Intravaginal administration, PGF_{2α}-methylester suppositories, mid-trimester abortion, 141

CONTRACEPTION

- Iron and iron binding capacity, serum, effect of Lippes IUD, 195
IUD (intrauterine device)
Levonorgestrel, investigation of pharmacokinetics, 207
Levonorgestrel-releasing IUD, menstrual blood loss, 153
LH-RH (luteinizing hormone releasing hormone),
analogue, stimulatory, effect on ovulation, 537
LH-RH stimulation, pituitary response during oral contraceptive therapy, 1
Lippes IUD, effect on hemoglobin, hematocrit, serum iron and iron binding capacity, 195
Lippes loop, immediate post-abortal insertion, 237
Lippes loop D, menstrual blood loss, 153
Long-acting contraceptive steroid formulations, assay (rabbit), 365
Luteinizing hormone releasing hormone (LH-RH),
effect of bromocriptine upon pituitary stimulation, 79
effect of oral contraceptives upon pituitary stimulation, 79
pituitary response during Danazol treatment after ovariectomy (rat), 283
pituitary responsiveness during Danazol treatment, male (rat), 61
Luteolytic efficacy of estradiol cyclopentylpropionate (rat), 163
Male antifertility agent,
α-chlorohydrin, 93, 413, 523
Danazol, 61, 283
monothioglycerol, 413
5-thio-D-glucose, 123, 413
Male fertility, effects of monothioglycerol, alpha-chlorohydrin and 5-thio-D-glucose (hamster), 413
Male sterilization reversal, report of workshop, 435
15-Me-PGF_{2α} ((15S)-15-methyl prostaglandin F_{2α} methyl ester)
15-Me-PGF_{2α} methyl ester (15(S)-15-methyl-prostaglandin F_{2α} methyl ester)
Mechanisms of action, progesterone-releasing IUD (rabbit), 475
Medroxyprogesterone acetate, blood level of injectable formulation (rabbit), 365
Medroxyprogesterone acetate, injectable,
bleeding patterns, 395
multinational comparative clinical evaluation, 395
side effects, 395
Menstrual blood loss, IUDs, 153
Mestranol + norethindrone,
effect on vitamin E status, 499
pituitary response to LH-RH stimulation, 1
Mid-trimester abortion, intravaginal administration of PGF_{2α}-methylester suppositories, 141
Milk, human, ethinyl estradiol level after oral administration, 131

CONTRACEPTION

- Mitotic patterns of uterus in early pregnancy, effect of U11,100A and U11,555A (rat), 329
Monothioglycerol, effect on male fertility (hamster), 413
Multinational comparative clinical evaluation, injectable NET-OEN and DMPA, 395
NET-OEN (norethisterone oenanthate)
Norethindrone, circulating levels, single silastic implant containing norethindrone acetate, 375
Norethindrone acetate,
 clinical evaluation of single silastic implant-D, 341
 single silastic implant, circulating levels of norethindrone, 375
Norethindrone acetate implant, endometrial histology and progesterone levels, 103
Norethindrone-releasing silicone rubber vaginal devices, 221
Norethisterone,
 effect on disulphide and sulphhydryl groups in cervical mucus, 35
 effect on trace metal content in cervical mucus, 35
 injectable sustained release system (baboon), 253
 plasma level with norethisterone-releasing IUD, 115
Norethisterone oenanthate (NET-OEN),
 blood level of injectable formulation (rabbit), 365
Norethisterone oenanthate, injectable,
 bleeding patterns, 395
 multinational comparative clinical evaluation, 395
 side effects, 395
Norethisterone-releasing IUD,
 influence on ovarian function, 115
 menstrual blood loss, 153
 plasma levels norethisterone, 115
Norgestrel pelargonate, blood level of injectable formulation (rabbit), 365
d-Norgestrel,
 plasma concentration, immediate postabortal contraception, 9
 plasma concentrations during use of d-norgestrel-releasing IUD, 569
 serum level with d-norgestrel silastic capsules, 315
 silastic capsules, bleeding and serum d-norgestrel, estradiol and progesteorne patterns, 315
d-Norgestrel-releasing IUD, plasma concentrations of d-norgestrel, 569
d-Norgestrel-releasing silicone rubber vaginal devices, 221
dl-Norgestrel + ethinyl estradiol, post-coital contraception, 247
Oral contraception,
 immediate postabortal, plasma concentrations of ethinylestradiol and d-norgestrel, 9
 immediate postabortal microdose ethinylestradiol + d-norgestrel, 297

CONTRACEPTION

- serious complication in insulin-dependent diabetics, 291
- Oral contraceptives,
effect on vitamin E status, 499
effect upon pituitary response by LH-RH and TRH, 79
ethinyl estradiol in human milk and plasma, 131
pituitary response to LH-RH stimulation, 1
plasma prolactin level, 71
- Org 2154 (16 α -ethyl-21-hydroxy-19-nor-pregn-4-ene-3,20-dione-21-dodecanoate),
blood level of injectable formulation (rabbit), 365
- Org 3236 (3-ethyl-11-methylene-18,19-dinor-17 α -pregn-4-en-20-yn-3-one),
effect on pituitary-ovarian function, 19
- Ovarian function,
influence by norethisterone-releasing IUD, 115
suppression by immediate postabortal contraception
with ethinylestradiol + d-norgestrel, 169
- Ovariectomy, effect of Danazol on gonadotropin secretion
(rat), 283
- Ovulation, effect of stimulatory LH-RH analogue, 537
- Ovulation blockade, ergocornine methanesulphonate (rat), 407
- Oxidized spermine (N,N^1 -bis(3-propionaldehyde)1,4-diaminobutane),
specific inhibition of spermatozoal energy metabolism, 423
- Parity, effect on pelvic inflammatory disease during IUD
use, 563
- Pelvic inflammatory disease, effect of parity during IUD
use, 563
- Penetration of foreign eggs, evaluation of fertilizing
capacity of human spermatozoa, 87
- PG (prostaglandin)
- PGF₂ α -methyleneester suppositories, mid-trimester abortion
induced by intravaginal administration, 141
- Pharmacokinetic investigations, levonorgestrel, 207
- Phospholipid analysis, effect on testis-epididymis complex
after α -chlorohydrin (rat), 523
- Pituitary function, suppression by immediate postabortal
contraception with ethinylestradiol +
d-norgestrel, 169
- Pituitary response to LH-RH, effect of Danazol after
ovariectomy (rat), 283
- Pituitary response to LH-RH stimulation, oral contraceptive therapy, 1
- Pituitary responsiveness to LH-RH, effect of Danazol, male
(rat), 61
- Pituitary-ovarian function, effect of Org 3236, 19
- PMSG (pregnant mare's serum gonadotropin)

CONTRACEPTION

- Postabortal,
 immediate ethinylestradiol + d-norgestrel, 9
 immediate IUD insertion, 237
 immediate microdose ethinylestradiol + d-norgestrel,
 169, 297
- Post-coital contraception, ethinyl estradiol + dl-norgestrel,
 247
- Post-ovulatory interceptive, conjugated estrogen, 443
- Postpartum, early, insertion of copper IUD, 355
- Preclinical evaluation of intrauterine progesterone as a
 contraceptive agent (rabbit), 465, 475, 489
- Pregnant mare's serum gonadotropin (PMSG),
 antifertility efficacy (rat), 547
- Progesterone, reversal of ergocornine blockade of ovulation
 (rat), 407
- Progesterone levels,
 effect of norethindrone acetate implant, 103
 effect of U11,100A and U11,555A (rat), 329
 following abortion by 15(S)15-methyl-PGF₂ α -methyl
 ester suppositories, 183
 immediate postabortal contraception with ethinyl-
 estradiol + d-norgestrel, 297
- Progesterone pattern, d-norgestrel silastic capsules, 315
- Progesterone-releasing IUD,
 effect on fibrinolytic activity of endometrium, 531
 embryology and toxicology (rabbit), 489
 local contraceptive effects and their reversal (rabbit),
 465
 menstrual blood loss, 153
 possible mechanisms of action (rabbit), 475
- Progesterone-releasing silicone rubber vaginal devices, 221
- Progesterogen-releasing silicone rubber vaginal devices, 221
- Prolactin,
 plasma level during oral contraception, 71
 plasma level during use of IUDs, 71
- Prostaglandin (PG),
 PGF₂ α -methylester vaginal suppositories, 141
 15(S)15-methyl-PGF₂ α methyl ester, single vaginal
 suppository, 267, 383, 455
 15(S)15-methyl-PGF₂ α -methyl ester vaginal suppositories,
 183
 silastic device containing 15-Me-PGF₂ α , 51
- Prostaglandin concentration, plasma, single 15-Me-PGF₂ α
 methyl ester vaginal suppository, 383
- Quinacrine hydrochloride, toxic effects (rodents), 231
- Radioimmunoassay method, ethinyl estradiol in human milk, 131
- Reversal of sterilization, male and female, report of
 workshop, 435
- Reversible sterilization devices, male and female, report of
 workshop, 435

CONTRACEPTION

- (15S)-15-methyl prostaglandin F_{2α} methyl ester (15-Me-PGF_{2α})
15(S)-15-methyl-prostaglandin F_{2α} methyl ester (15-me-PGF_{2α} methyl ester),
abortifacient effectiveness of single vaginal suppository, 383
early abortion by vaginal suppositories, 183
plasma prostaglandin concentration, single vaginal suppository, 383
vaginal suppositories, blood loss in relation to elimination of serum HCG, 183
vaginal suppository, clinical and hormonal studies, 267
vaginal suppository, single dose schedule, 455
Scanning electronmicroscopy, cervical mucus, 27
Second trimester abortion, 15(S)-15-methyl-PGF_{2α} methyl ester vaginal suppository, 267
Sialic acid levels in cervical mucus, 27
Side effects, comparative clinical evaluation of injectable NET-OEN and DMPA, 395
Silastic^R (dimethyl polysiloxane)
Silastic capsules of d-norgestrel, bleeding and serum d-norgestrel, estradiol and progesterone patterns, 315
Silastic device containing 15-Me-PGF_{2α}, efficacy in inducing abortion, 51
interruption of early pregnancy, 51
mode of action, 51
Silastic implant containing norethindrone acetate, circulating levels of norethindrone, 375
Silastic implant-D containing norethindrone acetate, clinical evaluation, 341
Silicone rubber vaginal devices, progestogen-releasing, 221
Single dose schedule, 15(S)15 methyl PGF_{2α} methyl ester vaginal suppository, 455
Single 15(S)15-methyl-PGF_{2α} methyl ester vaginal suppository, clinical and hormonal studies, 267
Single silastic implant containing norethidrone acetate, circulating levels of norethindrone, 375
Single silastic implant-D containing norethindrone acetate, clinical evaluation, 341
Specific inhibition of spermatozoal energy metabolism by oxidized spermine, 423
Spermatozoa, human, fertilizing capacity evaluated by penetration of foreign eggs, 87
Spermatozoal energy metabolism, specific inhibition by oxidized spermine, 423
Sterilization reversal, male and female, report of workshop, 435


CONTRACEPTION

- Stimulatory LH-RH analogue, effect on ovulation, 537
Subdermal polysiloxane capsules, d-norgestrel, 315
Subdermal single silastic implant, norethindrone acetate, 375
Subdermal single silastic implant-D containing norethindrone acetate, clinical evalution, 341
Suppositories,
 PGF_{2α}-methylester, mid-trimester abortion induced by intravaginal administration, 141
 vaginal, 15(S)15-methyl-PGF_{2α}-methyl ester for early abortion, 183
Suppository, single vaginal insertion of 15(S)15-methyl-PGF_{2α} methyl ester, 267, 383, 455
Sustained release norethisterone system, injectable (baboon), 253
Testing of vaginal contraceptive devices, progestogen-releasing, 221
Testis-epididymis complex, effect on phospholipid analysis after α-chlorohydrin (rat), 523
5-Thio-D-glucose,
 antifertility activities, male (mouse, rat), 123
 effect on male fertility (hamster), 413
Thyrotropin releasing hormone (TRH),
 effect of bromocriptine upon pituitary stimulation, 79
 effect of oral contraceptives upon pituitary stimulation, 79
Toxic effects of quinacrine hydrochloride (rodents), 231
Toxicology, progesterone-releasing IUD (rabbit), 489
Trace metal content, cervical mucus, 35
TRH (thyrotropin releasing hormone)
U11,100A and U11,555A,
 effect on plasma hormones (rat), 329
 effect on uterine mitoses in early pregnancy (rat), 329
Urea abortion, bacteriologic culture results, 513
Uterine mitoses in early pregnancy, effect of U11,100A and U11,555A (rat), 329
Vaginal contraceptive devices, fabrication and testing, 221
Vaginal suppositories of 15(S)15-methyl-PGF_{2α}-methyl ester, early abortion, 183
Vaginal suppository, single insertion of 15(S)15-methyl-PGF_{2α} methyl ester, 267, 383, 455
Vaginally deposited autonomic drugs, influence on fertility (rabbit), 309
Vitamin E status, effect of oral contraceptives, 499

Volume 17 1978
January - June
ISSN 0010 - 7824

CONTRACEPTION

AN INTERNATIONAL JOURNAL



DANIEL R. MISHELL, Jr., M.D.—Editor

Publisher: GERON-X, INC., LOS ALTOS, CALIF.

BOARD OF ASSOCIATE EDITORS

- Wendy Baldwin, Ph.D.
Behavioral Sciences Branch
Center for Population Research
National Institute of Child Health
and Human Development
Bethesda, Maryland 20014
- Gerald S. Bernstein, Ph.D., M.D.
Associate Professor
Department of Obstetrics and
Gynecology
USC School of Medicine
Los Angeles, California 90033
- M. C. Chang, Ph.D., Sc.D.
Senior Scientist
Worcester Foundation for
Experimental Biology
Shrewsbury, Massachusetts 01545
- Philip A. Corman, M.D.
Director of Population Research
National Institute of Child Health
and Human Development
Bethesda, Maryland 20014
- Uwe Goebelsmann, M.D.
Director of the Reproductive
Endocrinology Laboratory
Women's Hospital
1240 North Mission Road
Los Angeles, California 90033
- Elsimar Coutinho, M.D.
Professor
Department of Biochemistry and
Obstetrics
University of Bahia
Salvador, Bahia, BRAZIL
- P. Giorgio Crosignani, M.D.
Professor Incaricato di
Endocrinologia Ginecologica
alla Facoltà di Medicina
Dell'Università di Milano
20122 Milano, ITALY
Via Commenda 12
- Egon Diczfalusy, M.D.
Professor
Reproductive Endocrinology
Research Unit
Swedish Medical Research Council
Karolinska Sjukhuset,
Stockholm 60, SWEDEN
- J. Ferin, M.D.
Professor
Physiology of Human Reproduction
Research Unit
University of Louvain Hospital
Louvain, BELGIUM
- Carlos Gual, M.D.
Instituto Nacional de la Nutricion
Hospital de Enfermedades de la
Nutricion
Av. San Fernando y
Viaducto Tlalpan
MEXICO 22, D.F., MEXICO
- Joseph W. Goldzieher, M.D.
Director, Division of Clinical
Sciences
Southwest Foundation for
Research and Education
San Antonio, Texas 78228
- Roy O. Greep, Ph.D.
Director
Laboratory of Human Reproduction
& Reproductive Biology
Harvard Medical School
45 Shattuck Street
Boston, Massachusetts 02115
- Roy Hertz, M.D., Ph.D.
Research Professor
Departments of Pharmacology
and Obstetrics and Gynecology
George Washington University
Medical Center
Washington, D.C. 20037
- William D. Odell, M.D.
Professor and Chairman
Department of Medicine
Harbor General Hospital
U.C.L.A. School of Medicine
Torrance, California 90509
- C. Alvin Paulsen, M.D.
Professor of Medicine
Department of Medicine
University of Washington
School of Medicine
Seattle, Washington 98114

Corresponding Editors for CONTRACEPTION

- I. Hallbrecht, M.D.
Professor
Department of Obstetrics and
Gynecology
Tel Aviv University Medical School
Tel Aviv, ISRAEL
- Prof. Dr. J. Hammerstein
Abt. Gynaek. Endokrinologie
Sterilität und Familienplanung
Freie Universität Berlin
Hindenburghdamm 30
1000 Berlin 45
FEDERAL REPUBLIC GERMANY
- Professor Doctor A. A. Haspels
Department of Obstetrics and
Gynecology
Academic Hospital
University of Utrecht
Catharijnesingel 101
Utrecht, NETHERLANDS
- Tapani Luukkainen, M.D.
Steroid Research Laboratory
University of Helsinki
Department of Medical Chemistry
Siltavuorenpenger 10 A
SF-00170 Helsinki 17, FINLAND
- John R. Newton, M.B.
Department of Obstetrics and
Gynecology
King's College Hospital Medical
School
University of London
Denmark Hill
London, SE5 8RX
ENGLAND
- John J. Sciarra, M.D., Ph.D.
Chief of Staff
Prentice Women's Hospital and
Maternity Center
333 East Superior St.
Chicago, Illinois 60611
- Sheldon Segal, Ph.D.
Director, Biomedical Division
The Population Council
Rockefeller University
York Avenue and 66th Street
New York, New York 10021
- William N. Spellacy, M.D.
Professor and Chairman
Department of Obstetrics and
Gynecology
The University of Florida
College of Medicine
Gainesville, Florida 32610
- Howard J. Tatum, Ph.D., M.D.
Associate Director
Biomedical Division
The Population Council
The Rockefeller University
New York, New York 10021
- Dr. M. R. N. Prasad
Professor of Zoology
University of Delhi
Delhi 7, INDIA
- Dr. (Mrs.) Shanta S. Rao
Reproductive Physiology Unit
Indian Council of Medical Research
Seth G. S. Medical College
Parel, Bombay 12, INDIA
- Rodney P. Shearman
Professor of Obstetrics and
Gynecology
The University of Sydney
Sydney 2006, NSW
AUSTRALIA
- Sabita Tejuja, M.D.
Deputy Director General
Contraceptive Testing Unit
Indian Council of Medical Research
Ansair Nagar
Post Box 4508
New Delhi- 110016
INDIA
- Martin P. Vessey, M.D.
Professor, University Department of
Social and Community Medicine
University of Oxford
8 Keble Road
Oxford, OX1 3 QN
ENGLAND
- Juan Zanartu, M.D.
Associate Professor
Department of Experimental
Fertility
Universidad de Chile Clinica
Obstetrica
Hospital "Jose Joaquin Aguirre"
Casilla 6637
Santiago, CHILE

CONTRACEPTION

January 1978

Volume 17, Number 1

Pituitary Response to LHRH Stimulation in Women on Oral Contraceptives L.S. Wan, G. Weiss and M. Ganguly.....	1
Plasma Concentrations of Ethinylestradiol and D-Norgestrel during Two Immediate Postabortal Oral Contraceptive Cycles P. Lähteenmäki and C. G. Nilsson.....	9
Effects of a New Oral Progestagen on Pituitary-Ovarian Function L. Viinikka, S. Nummi, O. Ylikorkala, P. Virkkunen, T. Ranta, U. Alapiessa and R. Vihko.....	19
Sialic Acid Levels and Scanning Electronmicroscopy of Cervical Mucus B. Daunter.....	27
The Effect of a Low Dose Progestagen on the Trace Metal Content and Disulphide and Sulphydryl Groups in Cervical Mucus B. Daunter, E. N. Chantler and M. Elstein.....	35
A Study on the Contraceptive Effectiveness of a Newly Designed IUD "FD-1" in Japan T. Wagatsuma, S. Sakamoto, E. Matsuyama, Y. Amenomori, T. Kobayashi, M. Takada, S. Matsuda, S. Fujimoto, T. Shimizu, M. Suzuki, A. Ishihama, T. Nakanishi, S. Sunouchi and K. Sekiba.....	41
Interruption of Early Pregnancy with a Silastic Device Containing (15S)-15-Methyl Prostaglandin F _{2α} Methyl Ester: Efficacy and Mode of Action Johann H. Duenhoelter, Rigoberto Santos Ramos, Leon Milewich and Paul C. Macdonald.....	51
Danazol Effects on Gonadotropin Basal Levels and Pituitary Responsiveness to LH-RH in Immature Male Rats E. Pedroza, J. A. Vilchez-Martinez, A. Arimura and A. V. Schally	61
Plasma Prolactin Levels and Contraception: Oral Contraceptives and Intrauterine Devices William N. Spellacy, Charles S. Mahan, William C. Buhi and Virginia S. Dumbaugh	71
The Effect of Oral Contraceptives and of Bromocriptine upon Pituitary Stimulation by LH-RH and TRH J. S. E. Dericks-Tan, L. Eberlein, C. Streb and H.-D. Taubert	79
Fertilizing Capacity of Human Spermatozoa Evaluated by Actual Penetration of Foreign Eggs C. Barros, J. González, E. Herrera and E. Bustos-Obregón.....	87
Glycosidase Activity in Epididymal Epithelial Cells Isolated from Normal and α-Chlorhydrin Treated Male Rats W. R. Kemp and G. J. Killian	93

CONTRACEPTION is published monthly by Geron-X, Inc.
Box 1108, Los Altos, California 94022, USA.

© 1978, Geron-X, Inc.

Two Volumes per year

Personal Subscription	\$ 60
Institutional Subscription	\$100
Add \$7 for surface postage outside USA	
Add \$16 for airmail USA. Add \$36 for airmail outside USA	

Second-class postage paid at Los Altos, Calif. 94022, and at additional mailing office.

CONTRACEPTION

February 1978

Volume 17, Number 2

Endometrial Histology and Progesterone Levels in Women Using Norethindrone Acetate Implants for Contraception D. Takkar, S. Jeyaseelan, G. Kinra, K. R. Laumas and V. Hingorani	103
Contraception with a Norethisterone-Releasing IUD. Plasma Levels of Norethisterone and Its Influence on the Ovarian Function C. G. Nilsson, T. Luukkainen and P. Lähteenmäki	115
Antifertility Activities of 5-Thio-D-Glucose in Mice and Rats T. J. Lobl and S. E. Porteus.	123
Ethinyl Estradiol in Human Milk and Plasma after Oral Administration Staffan Nilsson, Karl-Gösta Nygren and Elof D. B. Johansson.	131
Mid-Trimester Abortion Induced by Intravaginal Administration of Prostaglandin F _{2α} -Methylester Suppositories A. S. van den Bergh and A. A. Haspels	141
Intrauterine Devices and Menstrual Blood Loss: A Comparative Study of Eight Devices During the First Six Months of Use Alfredo J. Gallegos, Ramon Aznar, Guillermina Merino and Elda Guizer	153
Estrogen and Female Fertility. II. Indomethacin and the Reversal of the Luteolytic Efficacy of Estradiol Cyclopentylpropionate Amar Chatterjee, Kakoli Sen and Rita Basu	163
Immediate Postabortal Contraception with a Microdose Combined Preparation: Suppression of Pituitary and Ovarian Function and Elimination of HCG P. Lähteenmäki and T. Luukkainen.	169
Early Abortion by Vaginal Prostaglandin Suppositories: Blood loss in relation to elimination of serum chorionic gonadotrophin, progesterone and estradiol-17β L. Hamberger, L. Nilsson, E. Björn-Rasmussen, P. Atterfelt and N. Wiqvist.	183

CONTRACEPTION

March 1978

Volume 17, Number 3

- Effect of the Lippes IUD on the Circulating Levels of Hemoglobin,
Hematocrit, Serum Iron and Iron Binding Capacity in Normal Women
Roberto Rivera, Jose R. Gaitan, Cesar L. Navarro, Juan Valles,
Hector Almonte, Rosario Ruiz and Ana B. Hernandez 195
- Investigations of Pharmacokinetics of Levonorgestrel to Specific Consideration
of a Possible First-Pass Effect in Women
M. Hümpel, H. Wendt, G. Pommerenke, Chr. Weiss and U. Speck 207
- Fabrication and Testing of Vaginal Contraceptive Devices Designed for Release
of Prespecified Dose Levels of Steroids
F. G. Burton, W. E. Skins, N. R. Gordon, J. T. Veal,
D. R. Kalkwarf and G. W. Duncan 221
- Observation on Toxic Effects of Quinacrine Hydrochloride (in Rodents)
Leonard A. Ciaccio, James L. Hill and Fred A. Kincl 231
- Post-Abortal Immediate IUD Insertion: Further Experience and a Controlled
Comparison of Three Devices
John A. Ross and Ho Youn Kwon 237
- Post-Coital Contraception Using dl-Norgestrel/Ethynodiol Estradiol Combination
R. Percival Smith and Adrienne Ross 247
- Larger Animal Testing of an Injectable Sustained Release Fertility Control System
Joseph D. Gresser, Donald L. Wise, Lee R. Beck and John F. Howes 253
- Clinical and Hormonal Studies with 3 mg 15(S)15-Methyl-PGF_{2a} Methyl Ester
Long-Acting Single Vaginal Suppository
K. T. Jagannatha, C. P. Puri, G. Kinra, N. Agarwal, A. K. Jain,
S. A. Rahman, K. R. Laumas and V. Hingorani 267
- Effects of Danazol on Gonadotropin Secretion after Ovariectomy in Rats
J. A. Vilchez-Martinez, E. Pedroza, A. Arimura and A. V. Schally 283

CONTRACEPTION

April 1978

Volume 17, Number 4

Serious Complications of Oral Contraception in Insulin-Dependent Diabetics Judith M. Steel and L. J. P. Duncan291
Immediate Postabortal Contraception with a Microdose Combined Preparation: Gonadotropin, Estradiol and Progesterone Levels during the Last Treatment Cycle and after Discontinuation of Oral Contraceptives Pekka Lähteenmäki.....	.297
Influence of Vaginally Deposited Autonomic Drugs upon Fertility in the Rabbit Mathew J. Hyman and George R. Howe309
Bleeding and Serum d-Norgestrel, Estradiol and Progesterone Patterns in Women Using d-Norgestrel Subdermal Polysiloxane Capsules for Contraception Donald E. Moore, Subir Roy, Frank Z. Stanczyk and Daniel R. Mishell, Jr.....	.315
Effect of U11,100A and U11,555A on Plasma Hormones and Uterine Mitoses in Early Pregnancy in the Rat U.A. Siddiqui, J. Watson and P.J. Heald329
Long-Term Contraception by a Single Silastic Implant-D Containing Norethindrone Acetate in Women: A Clinical Evaluation D. Takkar, P.N. Anandalakmi, V.L. Chandra, S. Bhatnagar, H.S. Yadav, K.R. Laumas and V. Hingorani; U. Krishna, A. Mandleker and V.N. Purandare; V. Goel, A. Adatia and K.D. Virker.....	.341
Early Postpartum Insertion of Copper IUD L. Hagbard, C.-A. Ingemanson and B. Sorbe355
Assay of Long-Acting Contraceptive Steroid Formulations in Rabbits K. Fotherby, K. Shrimanker and B.N. Saxena.....	.365
Circulating Levels of Norethindrone in Women with a Single Silastic Implant V. Goyal, U.M. Joshi, V.K. Naik, and P.K. Devi375
Plasma Prostaglandin Concentration and Abortifacient Effectiveness of a Single Insertion of a 3 mg 15(S)-Methyl-Prostaglandin F _{2α} , Methyl Ester Vaginal Suppository Charles A. Ballard, Katherine Forte and Niels H. Lauersen383
Announcement393

CONTRACEPTION

May 1978

Volume 17, Number 5

Multinational Comparative Clinical Evaluation of Two Long-Acting Injectable Contraceptive Steroids: Norethisterone Oenanthate and Medroxyprogesterone Acetate.	
2. Bleeding Patterns and Side Effects	
World Health Organization Task Force on Long-Acting Systemic Agents for the Regulation of Fertility395
Blockade of Ovulation by Ergocornine in Rats and Its Reversal by Progesterone Manidipa Gupta and Amar Chatterjee407
Effects of Monothioglycerol, Alpha-Chlorohydrin and 5-Thio-D-Glucose on the Fertility of Male Hamster R.P. Das and R. Yanagimachi413
Specific Inhibition of Spermatozoal Energy Metabolism by Oxidized Spermine Pirkko Pulkkinen423
Reversal of Sterilization in the Male and Female: Report of a Workshop Gerald I. Zatuchni and John J. Sciarra435
Conjugated Estrogen as a Post-Ovulatory Interceptive Morris Notelovitz and David Sayre Bard443
Evaluation of a Single Dose Schedule of 15 (S) 15 Methyl PGF ₂ Alpha Methyl Ester Suppository for the Termination of 10-14 Weeks of Pregnancy G. Kinra, N. Agarwal, K.T. Jagannath and V. Hingorani455
Preclinical Evaluation of Intrauterine Progesterone as a Contraceptive Agent. I. Local Contraceptive Effects and Their Reversal R. Hudson, P. Hemphill, S.A. Tillson465
Preclinical Evaluation of Intrauterine Progesterone as a Contraceptive Agent. II. Possible Mechanisms of Action S.A. Tillson, R. Hudson, D. Swisher and P. Leong475
Preclinical Evaluation of Intrauterine Progesterone as a Contraceptive Agent. III. Embryology and Toxicology R. Hudson, B.B. Pharris, S.A. Tillson and F. Reno489

CONTRACEPTION

June 1978

Volume 17, Number 6

Vitamin E Status of Young Women on Combined-Type Oral Contraceptives C.C. Tangney and J.A. Driskell	499
Bacteriologic Culture Results Obtained Before and After Elective Midtrimester Urea Abortion R.T. Burkman, M.R. Spence, M.F. Atienza and T.M. King	513
Phospholipid Analysis in Testis-Epididymis Complex After Alpha- Chlorhydrin Administration N.R. Kalla and B. Singh	523
No Increase of the Fibrinolytic Activity of the Human Endometrium by Progesterone-Releasing IUD (Progestasert®) P. Liedholm, N.-O. Sjöberg, K. Srivastava and B. Åstedt	531
Inhibition of Ovulation in Women by Chronic Treatment With a Stimulatory LRH Analogue — A New Approach to Birth Control? S.J. Nilius, C. Bergquist and L. Wide	537
Pregnancy Mare's Serum Gonadotropin: V. Indomethacin or Cortisone and the Reversal of Antifertility Efficacy of Pregnancy Mare's Serum Gonadotropin T. Gupta and A. Chatterjee	547
Fertility Inhibition by Intraoviductal Copper Beads in Rabbits S. Quijada, X. Soza and H.B. Croxatto	553
Is Development of Pelvic Inflammatory Disease in Women Using Intra-Uterine Device Equal Regardless of Parity? A One Year Follow-up Study S. Osser, B. Gullberg, P. Liedholm and N.-O. Sjöberg	563
Determination of Plasma Concentrations of d-Norgestrel During a One Year Follow-up in Women With a d-Norgestrel-Releasing IUD C.G. Nilsson, T. Luukkainen and P. Lähteenmäki	569
Letter to the Editor	575
Announcements	583
Author Index for Volume 17	589
Subject Index for Volume 17	593

CONTRACEPTION is published monthly by Geron-X, Inc.
Box 1108, Los Altos, California 94022, USA.

© 1978, Geron-X, Inc.

Two Volumes per year

Personal Subscription	\$ 60
Institutional Subscription	\$100
Add \$7 for surface postage outside USA	
Add \$16 for airmail USA. Add \$36 for airmail outside USA	

Second-class postage paid at Los Altos, Calif. 94022, and at additional mailing offices.



CONTRACEPTION

INDEX TO VOLUME 18

AUTHOR INDEX

- Agarwal, N., 593
Alvarez, F., 151
Amtayakul, K., 253
Andrade, A.T.L., 191
Atkinson, L.E., 367
Austin, F., 485
Back, D.J., 127
Barnes, G., 577
Basu, R., 225
Bates, M.W., 127
Beck, L.R., 497
Beckman, L.J., 7
Benjamin, A., 59
Bernstein, G.S., 485
Birk, B.S., 121
Birk, S.A., 121
Bölk, M., 607
Brache, V., 151
Breckenridge, A.M., 127
Bremme, K., 551
Brenner, P.F., 615
Buhi, W.C., 121
Bye, P.G.T., 1, 535
Bygdeman, M., 551
Cameron, J., 577
Carter, G., 295
Cates, W., Jr., 561
Cedillo, J.R., 271
Chandra, H., 233
Chapekar, A., 59
Chatterjee, A., 225
Chaudhury, R.R., 137
Choudhury, S.D., 641
Connell, K.G., 571
Corbin, A., 105
Corrales, E.S., 271
Coutinho, E., 315, 335, 411
Crawford, F.E., 127
Croxatto, H.B., 315, 335,
 429, 441
Culver, R.M., 239
Das, C., 35, 51, 71
da Silva, A.R., 315, 335
Diaz, J., 429
Diaz, S., 315, 335, 429, 441
Domenzain, M.E., 271
Dubey, S.K., 23, 59
Dumbaugh, V.A., 121
Dusitsin, N., 137
Elder, M., 1, 535
Faundes, A., 151, 315, 335, 355
Fenoglio, C.M., 459
Fitzpatrick, R.W., 477
Fotherby, K., 1, 535
Fox, E.J., 507
Fuchs, F., 137
Gentzschein, E.K., 615
Gillmer, M.D.G., 507
Gioia, I.A., 277
Giwa-Osagie, O.F., 517
Goebelsmann, U., 615
Gray, R., 137
Gréen, K., 551
Grossman, R., 137
Guerra, M.O., 191
Gupta, P.D., 91
Hafez, E.S.E., 105
Hahn, D.W., 239
Hahnenberger, R., 171
Haspels, A.A., 635
Hatcher, R.A., 163, 561
Hew, L., 315, 335
Hingorani, V., 35, 593
Holma, P., 315, 335
Hoogen, H., 607
Houser, B.B., 7
Howard, G., 1, 535
Israngkum, C., 137
Jackanicz, T.M., 395
Jackson, H., 477
Jacobs, H.S., 507
Jain, A., 315, 335

CONTRACEPTION

INDEX TO VOLUME 18

AUTHOR INDEX (CONTINUED)


- Jamal, K., 593
Jaszczak, S., 105
Johansson, E.D.B., 171
Kaplay, S.S., 287
Kim-Farley, R.J., 561
Koch, O.R., 277
Kraft, L.A., 239
Kulkarni, P.P., 543
Kumar, S., 35
Lähteenmäki, P., 201
Laumas, K.R., 593
Laumas, V., 593
Lencioni, L.J., 277
Loewenstein, R., 163
Lövgren, T., 181
Lowry, S.L., 497
Lundberg, B., 181
Luukkainen, T., 201, 451
Mahan, C.S., 121
Malaviya, B., 233
Malik, B.K., 593
Manchanda, P.K., 641
Mattos, C.E.R., 315, 335
McDonald, O., 315, 335
Measham, A.R., 163
Millen, A., 485
Mishell, D.R., Jr., 615
Mohini, P., 59
Montes de Oca, V., 151
Moo Young, A.J., 367
Nash, H.A., 315, 335, 367,
 395
Nath, I., 91
Neuwirth, R.S., 459
Newton, J., 577
Newton, J.R., 517
Newton, P., 577
Nielsen, N.C., 315, 335
Nieschlag, E., 607
Nigam, S.C., 233
Nilsson, C.G., 451
Nilsson, S., 469
Nuwayser, E.S., 459
Nygren, K.-G., 469
Öhman, L., 171
Onthuam, Y., 137
Orme, M. L'E., 127
Ortiz, A., 615
Ory, H.W., 561
Osler, M., 315, 335
Patel, K.L., 543
Pavez, M., 429, 441
Peluso, J., 105
Pettersson, K., 181
Polidoro, J.P., 239
Poulson, A.M., Jr., 295
Prianishnikov, V.A., 213
Punnonen, R., 181
Quinteros, E., 429
Raghavan, S.V., 23
Ramakrishnan, S., 35, 51, 71
Ramanadham, M., 287
Ray, J., 59
Richart, R.M., 459
Robertson, D.N., 151, 315, 335,
 367, 395, 429
Rowe, P.H., 127
Salahuddin, M., 23, 35
Sanchez, F.A., 315, 335
Saunders, D.M., 527
Savage, J., 517
Schuster, H., 607
Segal, S., 315, 335
Seth, U., 593
Shahani, S.M., 543
Shandilya, N.L., 105
Shastri, N., 23, 59
Shearman, R.P., 527
Shrimanker, K., 1, 535
Shuter, B., 527
Siriwongse, T., 137
Sivasomboon, B., 253
Sivin, I., 151, 315, 335, 355
Smiles, G., 127
Smith, E., 127
Somboonsuk, A., 137
Spellacy, W.N., 121
Stanczyk, F.Z., 615
Stern, J., 315, 335, 355
Sundaram, K., 571
Talwar, G.P., 19, 23, 35, 51,
 59, 71, 91

CONTRACEPTION

INDEX TO VOLUME 18

AUTHOR INDEX (CONTINUED)

- | | |
|--------------------------|--------------------------|
| Tejuja, S., 641 | Wickings, E.J., 607 |
| Thanangkul, O., 253 | Wiese, J., 315, 335 |
| Toivonen, J., 201 | Williams, L.L., 315, 335 |
| van den Bergh, A.S., 635 | Zutshi, S., 233 |
| Weiss, C., 163 | |



CONTRACEPTION

INDEX TO VOLUME 18

SUBJECT INDEX

- Abortion, febrile spontaneous and IUD, 561
Activated adenosine triphosphatases, effect of oral contraceptives, 287
Amenorrhea on the pill, 507
Analysis of cases of missing IUD strings, 485
Anti-hCG immunization, 19
Anti-Pr- β -hCG-TT antibodies,
 differential affinity for hCG and hLH, 23
 discriminatory effect on gonadotropins, 35
Antigon-F, comparative controlled trial in Thailand, 137
Association constants, anti-Pr- β -hCG-TT antibodies for
 hCG and hLH, 23
Barrier methods, nurse specialists in family planning clinic, 577
Binding of estrogen to myometrial estrogen binding protein,
 effect of Cu²⁺ ions, 181
Biological activity of gonadotropins, effect of anti-Pr- β -hCG-TT antibodies, 35
Blood pressure, effect of subdermal implants, 335
Body weight, effect of subdermal implants, 335
Capsules, silastic,
 release of steroids and resulting plasma levels, 395
 steroid release, 367
Carrier protein preimmunization, immunogenicity of haptene-protein conjugates (rabbit, monkey), 571
 α -Chlorohydrin phosphate isomer, effect on glyceraldehyde-3-phosphate dehydrogenase, 477
Chloroquine, chemical occlusion of oviducts (monkey), 233
Cholesterol, effect of oral R2323, 121
Cholesterol as a matrix for controlled-release of progesterone (baboon), 497
Choroid plexus, immunofluorescence and electron microscopic studies after immunization with Pr- β -hCG-TT (monkey), 91
Clinical chemistry, treatment with progestogen implants, 441
Clinical experience, d-norgestrel-releasing IUD, 451
Clinical experience with implant contraception, 411
Clinical trial,
 subdermal implants containing norgestrienone, 429
 testosterone undecanoate for male fertility control, 607
Combined oral contraceptive,
 comparative study of synthetic vs. natural estrogen, 527
 failure of withdrawal bleeding, 507
Comparative clinical trial, R-2323 and levonorgestrel subdermal implants, 151
Comparative controlled trial in Thailand of three IUDs, 137

CONTRACEPTION

- Comparative study on combination oral contraceptives, synthetic vs. natural estrogen, 527
Concept of stem cells, 213
Confirmation of early pregnancy, use of radioreceptor test for HCG, 543
Contraception with long acting subdermal implants, 315, 335, 355
Contraceptive effects of native plants (rat), 191
Contraceptive perceptions and usage among women, 7
Contraceptive vaginal rings (CVR),
levonorgestrel, 395
norgestrel-estradiol, 201
pituitary and gonadal function, 201
release of steroids and resulting plasma level, 395
Controlled-release of progesterone, cholesterol as a matrix (baboon), 497
Copper IUD, TCu 200, compared to subdermal implants, 315, 335, 355
 Cu^{2+} ions, effect on binding of estrogen to myometrial estrogen binding protein, 181
CVR (contraceptive vaginal rings)
Detection of ovulation, change in finger-finger electro-potential readings, 295
Diaphragm, perceptions and usage among women, 7
Differences in activity of antisera raised against total gonadotropins vs. Pr- β -hCG-TT, 59
Differential affinity of anti-Pr- β -hCG-TT antibodies for hCG and hLH, 23
Discontinuation, injectable norethisterone oenanthate, 517
Discriminatory activity on gonadotropins, antisera raised against total gonadotropins vs. Pr- β -hCG-TT, 59
Discriminatory effect of anti-Pr- β -hCG-TT antibodies on gonadotropins, 35
Early first trimester pregnancy interruption, single vaginal 15-methyl-PGF₂ α -methyl ester, 551
Early pregnancy confirmation, use of radioreceptor test for HCG, 543
Electron microscopic studies, immunization with Pr- β -hCG-TT (monkey), 91
Electropotential difference in finger-finger contact, detection of ovulation, 295
Endometrial epithelium, model of functional-morphological structure, 213
Erythrocyte Na⁺ and K⁺, effect of oral contraceptives, 287
Estradiol and estriol vs. ethinyl estradiol, combined oral contraceptive, 527
Estrogen, effect of Cu^{2+} ions on binding to myometrial estrogen binding protein, 181
Estrogen binding protein in myometrial cytosol, effect of Cu^{2+} ions on binding of estrogen, 181
Estrogen in combination oral contraceptives, synthetic vs. natural, 527

CONTRACEPTION

- Ethinyl estradiol,
metabolism by everted sacs of ileum (rat), 127
plasma level after oral administration, 469
radioimmunoassay of plasma, 469
- Ethinyl estradiol vs. estradiol and estriol, combined oral contraceptive, 527
- Everted sacs of ileum, metabolism of ethynodiol diacetate and norethindrone (rat), 127
- Extra-amniotic prostaglandins for termination of pregnancies, 641
- Eye, topical administration of norethindrone and progesterone (monkey), 171
- Failure of withdrawal bleeding, combined oral contraceptive therapy, 507
- Fallopian tubes, intratubal devices (monkey), 459
- Family planning clinic, nurse specialists, 577
- Febrile spontaneous abortion and IUD, 561
- Fertility, effect of intravas device (rabbit), 239
- Functional-morphological model of structure of endometrial epithelium, 213
- Glucose, level in blood after oral R2323, 121
- Glyceraldehyde-3-phosphate dehydrogenase, effect of α -chlorhydrin phosphate isomer, 477
- Gonadal function, use of norgestrel-estradiol CVR, 201
- Hapten-protein conjugates, effect of preimmunization with carrier protein (rabbit, monkey), 571
- hCG and hLH, differential affinity of anti-Pr- β -hCG-TT antibodies, 23
- hCG and hLH injections, progesterone level during luteal phase after immunization with Pr- β -hCG-TT (monkey), 51
- hCG and LH neutralization, Pr- β -hCG-TT vs. total gonadotropins antisera, 59
- hCG challenge, nature of immune complexes formed after immunization with Pr- β -hCG-TT (monkey), 71
- HCG radioreceptor test, 543
- Hemoglobin level, effect of subdermal implants, 335
- Hepatic function, effects of quinestrol (rat), 277
- High risk population, minilaparotomy as a primary interval sterilization procedure, 271
- Histology of reproductive tract, effect of intravas device (rabbit), 239
- Identification of IUD, do women know which they are wearing, 163
- Immune complexes formed, immunization with Pr- β -hCG-TT challenged with hCG (monkey), 71
- Immunization, anti-hCG, 19
- Immunofluorescence studies, immunization with Pr- β -hCG-TT (monkey), 91
- Immunogenecity of hapten-protein conjugates, preimmunization against carrier protein (rabbit, monkey), 571
- Implant, progesterone released from cholesterol pellets (baboon), 497

CONTRACEPTION

- Injectable contraception, nurse specialists in family planning clinic, 577
Injectable contraceptive, medroxyprogesterone acetate, 253
Injectable norethisterone oenanthate,
 occurrence of ovulation, 535
 study of patients discontinuing, 517
Injections of norethisterone oenanthate, plasma level of
 norethisterone, 1
Insulin, effect of oral R2323, 121
International clinical trial, subdermal implants, 315, 335,
 355
Interval sterilization, minilaparotomy in high risk population, 271
Intra-amniotic prostaglandins for termination of pregnancies, 641
Intraamniotic sulprostone, second trimester pregnancy termination, 635
Intratubal device, evaluation of polymer flock and metal alloy devices (monkey), 459
Intrauterine device (IUD),
 analysis of cases of missing strings, 485
 Antigon-F, comparative trial, 137
 comparative controlled trial in Thailand, 137
 do women know which they are wearing, 163
 febrile spontaneous abortion, 561
 Lippes loop C, comparative trial, 137
 d-norgestrel-releasing, 451
 nurse specialists in family planning clinic, 577
 perceptions and usage among women, 7
 TCu 200, compared to subdermal implants, 315, 335,
 355
 Ypsilon, comparative trial, 137
Intravas device,
 effect on fertility (rabbit), 239
 effect on histology of reproductive tract, 239
 effect on sperm output (rabbit), 239
Intravas device studies (rabbit), 239
Isomer of α -chlorohydrin phosphate, effect on glyceraldehyde-3-phosphate dehydrogenase, 477
IUD (intrauterine device)
Kidney, immunofluorescence and electron microscopic studies after immunization with Pr- β -hCG-TT (monkey), 91
Lactating women, serum level of norethindrone after norethindrone acetate implant, 593
Levonorgestrel (d-norgestrel),
 comparative clinical trial with subdermal implants, 151
 effects of subdermal implants, 335
 release from sustained release dosage forms and plasma level, 395
 release rate from silastic capsules and rods, 367
 subdermal implants, 315, 355
LH, effect on serum level by LH-RH peptide antagonist (monkey), 105

CONTRACEPTION

- LH-RH (luteinizing hormone-releasing hormone)
LH-RH peptide antagonist (Wy-18,185),
 effect on menstrual cycle (monkey), 105
 effect on ovulation (monkey), 105
 effect on serum LH (monkey), 105
Lippes loop C, comparative controlled trial in Thailand, 137
Luteal phase progesterone level, hLH and hCG after immunization with Pr- β -hCG-TT (monkey), 51
Luteinizing hormone-releasing hormone (LH-RH)
Lynestrenol, clinical experience with implant contraception, 411
Male fertility control,
 intravas device studies (rabbit), 239
 testosterone undecanoate, 607
Medroxyprogesterone acetate, vitamin and trace mineral metabolism, 253
Megestrol acetate,
 clinical experience with implant contraception, 411
 release from sustained release dosage forms and plasma levels, 395
 release rate from silastic capsules and rods, 367
Menstrual bleeding patterns, long acting contraceptive implants, 355
Menstrual cycle, effect of LH-RH peptide antagonist (monkey), 105
Menstrual pattern disturbance, effect of subdermal implants, 335
Metabolism of ethynodiol and norethindrone by everted sacs of ileum (rat), 127
Metal alloy, intratubal device (monkey), 459
15-Methyl-PGF₂ α -methyl ester, single vaginal administration, 551
Minilaparotomy, primary interval sterilization procedure in high risk population, 271
Missing IUD strings, analysis of cases, 485
Mode of action of prostaglandins, 225
Model of functional-morphological structure of endometrium, 213
Multicentric trial, intra- and extra-amniotic prostaglandins for termination of pregnancies, 641
Multiple injections of norethisterone enanthate, plasma level of norethisterone, 1
Myometrial estrogen binding protein, effect of Cu²⁺ ions on binding of estrogen, 181
(Na⁺, K⁺) and (Mg⁺⁺, Ca⁺⁺) activated adenosine triphosphatases, effect of oral contraceptives, 287
Native plants, contraceptive effects (rat), 191
Natural vs. synthetic estrogen, comparative study on combination oral contraceptives, 527
Nature of immune complexes formed, immunization with Pr- β -hCG-TT on challenge with hCG (monkey), 71
Neutralization of biological activity of gonadotropins, effect of anti-Pr- β -hCG-TT antibodies, 35
Neutralization of hCG and LH action, antisera raised against total gonadotropins vs. Pr- β -hCG-TT, 59

CONTRACEPTION

- Norethandrolone, release rate from silastic capsules and rods (rat), 367
- Norethindrone,
 clinical experience with implant contraception, 411
 metabolism by everted sacs of ileum (rat), 127
 radioimmunoassay, 593, 615
 release rate from silastic capsules and rods, 367
 serum concentration following oral norethindrone-containing contraceptive, 615
 serum level in lactating women after norethindrone acetate implant, 593
 topical administration in eye and nose (monkey), 171
- Norethindrone-containing oral contraceptive, serum norethindrone concentrations, 615
- Norethindrone acetate, release rate from silastic capsules and rods (rat), 367
- Norethindrone acetate and natural vs. synthetic estrogen, combined oral contraceptive, 527
- Norethisterone onenathate, plasma level of norethisterone, 1
- Norethisterone oenantate as injectable contraceptive,
 occurrence of ovulation, 535
 study of patients discontinuing, 517
- Norethisterone plasma levels, after injections of norethisterone oenanthate, 1
- d-Norgestrel (levonorgestrel),
 clinical experience with implant contraception, 411
 effects on metabolic parameters of subdermal implants, 441
- d-Norgestrel plasma concentrations, d-norgestrel-releasing IUD, 451
- Norgestrel-estradiol CVR, pituitary and gonadal function, 201
- d-Norgestrel-releasing IUD,
 clinical experience, 451
 plasma d-norgestrel concentrations, 451
- Norgestrieneone (17 α -ethynyl-17-hydroxy-estra-4,9,11-triene-3-one, R 2010),
 clinical experience implant contraception, 411
 clinical trial with subdermal implants, 429
 effects of subdermal implants, 335
 effects on metabolic parameters of subdermal implants, 441
 release from sustained release dosage forms and plasma level, 395
 release rate from silastic capsules, 367
 subdermal implants, 315, 355
- Nose, topical administration of norethindrone and progesterone (monkey), 171
- Nurse specialists in family planning clinic, 577
- Occlusion of oviducts, use of chloroquine (monkey), 233
- Oral administration of ethinyl estradiol, plasma levels, 469
- Oral combination contraceptive therapy, failure of withdrawal bleeding, 507
- Oral combination contraceptives, comparative study of synthetic vs. natural estrogen, 527

CONTRACEPTION

- Oral contraception, nurse specialists in family planning clinic, 577
- Oral contraceptive, effect on (Na^+ , K^+) and (Mg^{++} , Ca^{++}) activated adenosine triphosphatasases, 287
- norethindrone-containing, 615
- Oral weekly contraceptive, R2323, 121
- Ovarian function, effect of injectable norethisterone oenanthate, 535
- Oviduct, chemical occlusion with chloroquine (monkey), 233
- Ovulation, effect of LH-RH peptide antagonist (monkey), 105 occurrence during injectable norethisterone oenanthate, 535
- Ovulation detection, change in finger-finger electropotential readings, 295
- Perceptions and usage of contraceptives among women, 7
- PG (prostaglandin)
- $\text{PGF}_2\alpha$ -induced premature labor, involvement of progesterone (rat), 225
- Pill, perceptions and usage among women, 7
- Pituitary, immunofluorescence and electron microscopic studies after immunization with Pr- β -hCG-TT (monkey), 91
- Pituitary function, use of norgestrel-estradiol CVR, 201
- Pituitary gonadotropins, effect of anti-Pr- β -hCG-TT antibodies, 35
- Placental gonadotropins, effect of anti-Pr- β -hCG-TT antibodies, 35
- Plants, contraceptive effects (rat), 191
- Plasma Na^+ and K^+ , effect of oral contraceptives, 287
- Polymer flock, intratubal device (monkey), 459
- Pr- β -hCG-TT antibodies, differential affinity for hCG and hLH, 23 discriminatory effect on gonadotropins, 35
- Pr- β -hCG-TT immunization, immunofluorescence and electron microscopic studies (monkey), 91
- nature of immune complexes formed on challenge with hCG (monkey), 71
- progesterone level after hLH and hCG during luteal phase (monkey), 51
- Pr- β -hCG-TT vs. total gonadotropins antisera, neutralization of hCG and LH action, 59
- Pregnancy confirmation, use of radioreceptor test for HCG, 543
- Preimmunization with carrier protein, immunogenicity of hapten-protein conjugates (rabbit, monkey), 571
- Progesterone, involvement in initiation of $\text{PGF}_2\alpha$ -induced premature labor (rat), 225

CONTRACEPTION

- release from implanted cholesterol pellets (baboon), 497
topical administration in eye and nose (monkey), 171
Progesterone level after hLH and hCG during luteal phase, immunization with Pr- β -hCG-TT (monkey), 51
Progesterone-cholesterol pellets (baboon), 497
Progestin-estrogen combination, clinical experience with implant contraception, 411
Prostaglandin (PG),
 intra- and extra-amniotic for pregnancy termination, 641
 15-Me-PGF₂ α , 641
 15-methyl-PGF₂ α -methyl ester, 551
 PGF₂ α
 possible mode of action, 225
 sulprostone, 635
Quinestrol (3-cyclopentyl ether ethynodiol estradiol),
 effect on hepatic function (rat), 277
R-1364, clinical experience with implant contraception, 411
R2323 (13 β -ethyl-17 α -ethynodiol-17-hydroxy-gona-4,9,11-trien-3-one)
R2323 (17 β -hydroxy-17 α -ethynodiol-18-methyl-4,9,11-estriene-3-one),
 clinical experience with implant contraception, 411
 comparative clinical trial with subdermal implants, 151
 effect on blood glucose level, 121
 effect on cholesterol level, 121
 effect on insulin level, 121
 effect on triglyceride level, 121
 effects on metabolic parameters of subdermal implants, 441
 release rate from silastic capsules and rods, 367
R-5020 (17 α -21-dimethyl-19-norpregna-4,9-dien-3,20-dione),
 release rate from silastic capsules (rat), 367
Radioimmunoassay,
 norethindrone, 593, 615
 plasma levels of ethynodiol estradiol, 469
Radioreceptor test for HCG, 543
Reproductive tract histology, effect of intravas device (rabbit), 239
Rods, silastic,
 release of steroids and resulting plasma level, 395
 steroid release, 367
Second trimester pregnancy termination, intraamniotic sulprostone, 635
Silastic capsules and rods, steroid release, 367
Single vaginal administration, 15-methyl-PGF₂ α -methyl ester, 551
Sperm output, effect of intravas device (rabbit), 239
Spontaneous abortion, use of IUD, 561
ST 1435 (16-methylene-17 α -acetoxy-19-norpregn-4-en-3,20-dione),
 clinical experience with implant contraception, 411
 release rate from silastic capsules, 367

CONTRACEPTION

- Stem cells, concept of functional-morphological structure of endometrial epithelium, 213
Sterilization, minilaparotomy in high risk population, 271
Subdermal implants,
 analysis of menstrual bleeding patterns, 355
 clinical experience, 411
 clinical trial with norgestriene, 429
 comparative clinical trial of R-2323 and levonorgestrel, 151
 effective and acceptable contraceptive modality, 315
 effects in clinical trials, 335
 effects on metabolic parameters, 441
 levonorgestrel, 315, 335, 355, 367, 395
 lynestrenol, 411
 measured effects, 335
 megestrol acetate, 367, 395, 411
 norethandrolone, 367
 norethindrone, 367, 411
 norethindrone acetate, 367, 593
 d-norgestrel, 411, 441
 norgestriene, 315, 335, 355, 367, 395, 411, 429, 441
 perceived effects, 335
 progestin-estrogen combinations, 411
 R-1364, 411
 R2323, 367, 411, 441
 R-5020, 367
 release of steroids and resulting plasma level, 395
 serum level of norethindrone in lactating women, 593
 ST.1435, 367, 411
 steroid release, 367
 testosterone, 367
 testosterone propionate, 367
Subjects' impressions of changes, effect of subdermal implants, 335
Sulprostone (16-phenoxy- ω -17,18,19,20-tetranor-PGE₂-methyl-sulfonamide, SHB 286)
 intraamniotic administration for second trimester pregnancy termination, 635
Sulprostone with calcium gluconate, second trimester pregnancy termination, 635
Sulprostone with oxytocin, second trimester pregnancy termination, 635
Suppository, single 15-methyl-PGF₂ α -methyl ester, 551
Synthetic vs. natural estrogen, comparative study on combination oral contraceptives, 527
Testosterone, release rate from silastic capsules and rods, 367
Testosterone propionate, release rate from silastic rods (rat), 367
Testosterone undecanoate, clinical trial for male fertility control, 607
Topical administration, norethindrone and progesterone in eye and nose (monkey), 171

CONTRACEPTION


- Total gonadotropins vs. Pr- β -hCG-TT antisera, neutralization of hCG and LH action, 59
Trace mineral metabolism, use of medroxyprogesterone acetate, 253
Triglyceride, effect of oral R2323, 121
Type of IUD, do women know which they are wearing, 163
Usage and perceptions of contraceptives among women, 7
Use-related closures, injectable norethisterone oenanthate, 517
Vaginal administration, single 15-methyl-PGF₂ α -methyl ester, 551
Vasectomy, perceptions and usage among women, 7
Vitamin metabolism, use of medroxyprogesterone acetate, 253
Weekly oral contraceptive, R2323, 121
Withdrawal bleeding, failure during combined oral contraceptive therapy, 507
Wy-18,185 (D-(PHE)²-D-(ALA)⁶-LH-RH)
Ypsilon, comparative controlled trial in Thailand, 137

Volume 18 1978

July - December

ISSN 0010 - 7824

CONTRACEPTION



DANIEL R. MISHELL, Jr., M.D.—Editor

BOARD OF ASSOCIATE EDITORS

- Wendy Baldwin, Ph.D.**
Behavioral Sciences Branch
Center for Population Research
National Institute of Child Health
and Human Development
Bethesda, Maryland 20014
- Gerald S. Bernstein, Ph.D., M.D.**
Associate Professor
Department of Obstetrics and
Gynecology
USC School of Medicine
Los Angeles, California 90033
- M. C. Chang, Ph.D., Sc.D.**
Senior Scientist
Worcester Foundation for
Experimental Biology
Shrewsbury, Massachusetts 01545
- Philip A. Corfman, M.D.**
Director of Population Research
National Institute of Child Health
and Human Development
Bethesda, Maryland 20014
- Uwe Goebelmann, M.D.**
Director of the Reproductive
Endocrinology Laboratory
Women's Hospital
1240 North Mission Road
Los Angeles, California 90033
- Elsimar Coutinho, M.D.**
Professor
Department of Biochemistry and
Obstetrics
University of Bahia
Salvador, Bahia, BRAZIL
- P. Giorgio Crosignani, M.D.**
Professor Incaricato di
Endocrinologia Ginecologica
alla Facoltà di Medicina
Dell'Università di Milano
20122 Milano, ITALY
Via Commenda 12
- Egon Diczfalussy, M.D.**
Professor
Reproductive Endocrinology
Research Unit
Swedish Medical Research Council
Karolinska Sjukhuset,
Stockholm 60, SWEDEN
- J. Ferin, M.D.**
Professor
Physiology of Human Reproduction
Research Unit
University of Louvain Hospital
Louvain, BELGIUM
- Carlos Gual, M.D.**
Instituto Nacional de la Nutricion
Hospital de Enfermedades de la
Nutricion
Av. San Fernando y
Viaducto Tlalpan
MEXICO 22, D.F., MEXICO
- Joseph W. Goldzieher, M.D.**
Director, Division of Clinical
Sciences
Southwest Foundation for
Research and Education
San Antonio, Texas 78228
- Roy O. Greep, Ph.D.**
Director
Laboratory of Human Reproduction
& Reproductive Biology
Harvard Medical School
45 Shattuck Street
Boston, Massachusetts 02115
- Roy Hertz, M.D., Ph.D.**
Research Professor
Departments of Pharmacology
and Obstetrics and Gynecology
George Washington University
Medical Center
Washington, D.C. 20037
- William D. Odell, M.D.**
Professor and Chairman
Department of Medicine
Harbor General Hospital
U.C.L.A. School of Medicine
Torrance, California 90509
- C. Alvin Paulsen, M.D.**
Professor of Medicine
Department of Medicine
University of Washington
School of Medicine
Seattle, Washington 98114
- I. Halbreich, M.D.**
Professor
Department of Obstetrics and
Gynecology
Tel Aviv University Medical School
Tel Aviv, ISRAEL
- Prof. Dr. J. Hammerstein**
Abt. Gynäk. Endokrinologie
Sterilis. und Familienplanung
Freie Universität Berlin
Hindenburghdamm 30
1000 Berlin 45
FEDERAL REPUBLIC GERMANY
- Professor Doctor A. A. Haspels**
Department of Obstetrics and
Gynecology
Academic Hospital
University of Utrecht
Catharijnesingel 101
Utrecht, NETHERLANDS
- Tapani Luukkainen, M.D.**
Steroid Research Laboratory
University of Helsinki
Department of Medical Chemistry
Siltavuorenpenger 10 A
SF-00170 Helsinki 17, FINLAND
- John R. Newton, M.B.**
Department of Obstetrics and
Gynecology
King's College Hospital Medical
School
University of London
Denmark Hill
London, SE5 8RX
ENGLAND
- John J. Sciarra, M.D., Ph.D.**
Chief of Staff
Prentice Women's Hospital and
Maternity Center
333 East Superior St.
Chicago, Illinois 60611
- Sheldon Segal, Ph.D.**
Director, Biomedical Division
The Population Council
Rockefeller University
York Avenue and 66th Street
New York, New York 10021
- William N. Spellacy, M.D.**
Professor and Chairman
Department of Obstetrics and
Gynecology
The University of Florida
College of Medicine
Gainesville, Florida 32610
- Howard J. Tatum, Ph.D., M.D.**
Associate Director
Biomedical Division
The Population Council
The Rockefeller University
New York, New York 10021
- Dr. M. R. N. Prasad**
Professor of Zoology
University of Delhi
Delhi 7, INDIA
- Dr. (Mrs.) Shanta S. Rao**
Reproductive Physiology Unit
Indian Council of Medical Research
Seth G. S. Medical College
Parel, Bombay 12, INDIA
- Rodney P. Shearman**
Professor of Obstetrics and
Gynecology
The University of Sydney
Sydney 2006, NSW
AUSTRALIA
- Sabita Tejuja, M.D.**
Deputy Director General
Contraceptive Testing Unit
Indian Council of Medical Research
Ansari Nagar
Post Box 4508
New Delhi 110016
INDIA
- Martin P. Vessey, M.D.**
Professor, University Department of
Social and Community Medicine
University of Oxford
8 Keble Road
Oxford, OX1 3 QN
ENGLAND
- Juan Zanartu, M.D.**
Associate Professor
Department of Experimental
Fertility
Universidad de Chile Clínica
Obstetricia
Hospital "José Joaquín Aguirre"
Casilla 6637
Santiago, CHILE

CONTRACEPTION

July 1978

Volume 18, Number 1

Plasma Levels of Norethisterone After Single and Multiple Injections of Norethisterone Oenanthate

K. Fotherby, G. Howard, K. Shrimanker, M. Elder and P.G.T. Bye..... 1

Examination of Contraceptive Perceptions and Usage Among Los Angeles County Women
B.B. Houser and L.J. Beckman..... 7

Anti-hCG Immunization. Introduction
G.P. Talwar..... 19

Differential Affinity of Anti-Pr- β -hCG-TT Antibodies for hCG and hLH
N. Shastri, S.K. Dubey, S.V. Raghavan, M. Salahuddin and G.P. Talwar..... 23

Discriminatory Effect of Anti-Pr- β -hCG-TT Antibodies on the Neutralization of the Biological Activity of Placental and Pituitary Gonadotropins
C. Das, G.P. Talwar, S. Ramakrishnan, M. Salahuddin, S. Kumar, V. Hingorani, E. Coutinho, H. Croxatto, E. Hemmingson, E. Johansson, T. Luukkainen, S. Shahani, K. Sundaram, H. Nash and S.J. Segal 35

Progesterone Levels in Monkeys Immunized with Pr- β -hCG-TT After Injection of hLH and hCG During Luteal Phase
S. Ramakrishnan, C. Das and G.P. Talwar..... 51

Differences Between the Discriminatory Activity of Antisera Raised Against the Total Gonadotropins and the Pr- β -hCG-TT for Neutralization of hCG and hLH Action
P. Mohini, T.N. Chapekar, A. Benjamin J. Raj, N. Shastri, S.K. Dubey and G.P. Talwar 59

Nature of Immune Complexes Formed in Rhesus Monkeys Immunized With Pr- β -hCG-TT on Challenge With hCG
S. Ramakrishnan, C. Das and G.P. Talwar..... 71

Immunofluorescence and Electron Microscopic Studies on Kidney, Choroid Plexus and Pituitary in Rhesus Monkeys Immunized With the Anti-hCG Vaccine Pr- β -hCG-TT
P.D. Gupta, I. Nath and G.P. Talwar..... 91

CONTRACEPTION is published monthly by Geron-X, Inc.
Box 1108, Los Altos, California 94022, USA.

© 1978, Geron-X, Inc.

Two Volumes per year

Personal Subscription	\$ 60
Institutional Subscription	\$100

Add \$7 for surface postage outside USA
Add \$16 for airmail USA. Add \$36 for airmail outside USA

Second-class postage paid at Los Altos, Calif. 94022, and at additional mailing office.

CONTRACEPTION

August 1978

Volume 18, Number 2

Effect of LH-RH Peptide Antagonist on Serum LH, Ovulation and Menstrual Cycle of Crab-Eating Macaque A. Corbin, S. Jaszcak, J. Peluso, N.L. Shandilya and E.S.E. Hafez.....	105
Blood Glucose, Insulin, Cholesterol and Triglyceride Levels in Women Treated for Six Months with the Weekly Oral Contraceptive R2323 W.N. Spellacy, C.S. Mahan, W.C. Buhi, V.A. Dumbaugh, and S.A. Birk.....	121
Ethynelestradiol and Norethindrone Metabolism by Everted Sacs of Rat Ileum D.J. Back, M.W. Bates, A.M. Breckenridge, F.E. Crawford, M.L'E. Orme, P.H. Rowe, G. Smiles and E. Smith.....	127
A Comparative Controlled Trial in Rural Thailand of Three Intrauterine Devices A. Somboonsuk, C. Israngkum, T. Siriwongse, N. Dusitsin, Y. Onthuan, R.R. Chaudhury, F. Fuchs, R. Grossman and R. Gray.....	137
Comparative Clinical Trial of the Progestins R-2323 and Levonorgestrel Administered by Subdermal Implants F. Alvarez, D.N. Robertson, V. Montes de Oca, I. Sivin, V. Brache and A. Faundes.....	151
Do Women Know Which IUD They are Wearing? R.A. Hatcher, A.R. Measham, C. Weiss and R. Loewenstein.....	163
Topical Administration of Progestational Steroids in the Eye and Nose - A Rapid Absorption to the Blood L. Öhman, R. Hahnenberger and E.D.B. Johansson.....	171
Effect of Cu ²⁺ Ions on the Binding of Estrogen to the Human Myometrial Estrogen Binding Protein T. Lövgren, K. Pettersson, B. Lundberg and R. Punnonen	181
Contraceptive Effects of Native Plants in Rats M.O. Guerra and A.T.L. Andrade.....	191

CONTRACEPTION

September 1978

Volume 18, Number 3

Pituitary and Gonadal Function During the Use of Norgestrel-Estradiol Vaginal Rings Toivonen, J., Lähteenmäki, P. and Luukkainen, T.....	201
On the Concept of Stem Cell and a Model of Functional-Morphological Structure of the Endometrium Prianishnikov, V.A.....	213
The Possible Mode of Action of Prostaglandins: XIV Evidence of an Involvement of Progesterone in the Initiation of Prostaglandin F _{2α} -Induced Premature Labor in Rats Basu, R. and Chatterjee, A.....	225
Chemical Occlusion of Rhesus Monkey Oviducts With Chloroquine Chandra, H., Nigam, S.C., Zutshi, S. and Malaviya, B.....	233
Intravas Device Studies in Rabbits: II. Effects on Sperm Output, Fertility and Histology of the Reproductive Tract Kraft, L.A., Polidoro, J.P., Culver, R.M. and Hahn, D.W.....	239
Vitamin and Trace Mineral Metabolism in Medroxyprogesterone Acetate Users Amatayakul, K., Sivasomboon, B. and Thanangkul, O.....	253
Minilaparotomy as a Primary Interval Sterilization Procedure in a High Risk Population Domenzain, M.E., Corrales, E.S. and Cedillo, J.R.....	271
Effects of Quinestrol on Hepatic Function in the Rat Gioia, I., Lencioni, L.J. and Koch, O.R.....	277
Erythrocyte Membrane (Na ⁺ , K ⁺) and (Mg ⁺⁺ , Ca ⁺⁺) Activated Adenosine Triphosphatas in Women Using Oral Contraceptives - A Preliminary Report Kaplay, S.S. and Ramanadham, M.....	287
Detection of Ovulation by a Method of Change in Finger-Finger Electropotential Readings Poulson, A.M., Jr. and Carter, G.....	295
Announcements.....	309

CONTRACEPTION

October 1978

Volume 18, Number 4

Contraception With Long Acting Subdermal Implants: I. An Effective and Acceptable Modality in International Clinical Trials

- Coutinho, E., da Silva, A.R., Mattos, C.E.R., Nielsen, N.C., Osler, M., Wiese, J., Holma, P., Diaz, S., Croxatto, H.B., Sanchez, F.A., Faundes, A., Williams, L.L., Hew, L., McDonald, O., Segal, S., Nash, H., Robertson, D., Jain, A., Stern, J. and Sivin, I..... 315

Contraception With Long Acting Subdermal Implants: II. Measured and Perceived Effects in International Clinical Trials

- Coutinho, E., da Silva, A.R., Mattos, C.E.R., Nielsen, N.C., Osler, M., Wiese, J., Holma, P., Diaz, S., Croxatto, H.B., Sanchez, F.A., Faundes, A., Williams, L.L., Hew, L., McDonald, O., Segal, S., Nash, H., Robertson, D., Jain, A., Stern, J. and Sivin, I..... 335

Long Acting Contraceptive Implants: An Analysis of Menstrual Bleeding Patterns

- Faundes, A., Sivin, I. and Stern, J..... 355

Steroid Release From Silastic Capsules and Rods

- Nash, H.A., Robertson, D.N., Moo Young, A.J. and Atkinson, L.E..... 367

Release of Contraceptive Steroids From Sustained Release Dosage Forms and Resulting Plasma Levels

- Nash, H.A., Robertson, D.N. and Jackanicz, T.M..... 395

Clinical Experience With Implant Contraception

- Coutinho, E..... 411

Clinical Trials With Subdermal Implants Containing Norgestrienone

- Diaz, S., Pavez, M., Quinteros, E., Diaz, J., Robertson, D.N. and Croxatto, H.B..... 429

Clinical Chemistry in Women Treated With Progestogen Implants

- Croxatto, H.B., Diaz, S. and Pavez, M..... 441

Sustained Intrauterine Release of d-Norgestrel

- Luukkainen, T. and Nilsson, C.G..... 451

CONTRACEPTION

November 1978

Volume 18, Number 5

Evaluation of Polymer Flock and Metal Alloy Intra-tubal Device in Pigtail Monkeys Richart, R.M., Neuwirth, R.S., Nuwayser, E.S. and Fenoglio, C.M.	459
Ethinyl Estradiol in Peripheral Plasma After Oral Administration of 30 μ g and 50 μ g to Women Nilsson, S. and Nygren, K.-G.	469
Effect of Racemic and S(+) α -Chlorhydrin-1-Phosphate on Glyceraldehyde-3-Phosphate Dehydrogenase in Relation to its Contraceptive Action Fitzpatrick, R.W., Jackson, H. and Dickinson, N.A.	477
Analysis of 100 Cases of Missing IUD Strings Millen, A., Austin, F. and Bernstein, G.S.	485
<i>In Vivo</i> Evaluation of Cholesterol as a Matrix for the Controlled-Release of Progesterone Beck, L.R. and Lowry, S.L.	497
Failure of Withdrawal Bleeding During Combined Oral Contraceptive Therapy: 'Amenorrhoea on the Pill' Gillmer, M.D.G., Fox, E.J. and Jacobs, H.S.	507
Norethisterone Oenanthalate as an Injectable Contraceptive: A Study of Patients Discontinuing Treatment Giwa-Osagie, O.F., Savage, J. and Newton, J.R.	517
Comparative Studies on Two Combination Oral Contraceptives, One Containing Synthetic Estrogen, the Other "Natural" Estrogens Saunders, D.M., Shuter, B. and Shearman, R.P.	527
Occurrence of Ovulation in Women Receiving the Injectable Contraceptive Norethisterone Oenanthalate Fotherby, K., Howard, G., Shrimanker, K., Elder, M. and Bye, P.G.T.	535
Use of a Radioreceptor Test for HCG in Women Practicing Contraception Shahani, S.M., Kulkarni, P.P. and Patel, K.L.	543

CONTRACEPTION

December 1978

Volume 18, Number 6

Interruption of Early Trimester Pregnancy by Single Vaginal Administration of 15-Methyl-PGF _{2α} -Methyl Ester Grén, K., Bygdeman, M. and Bremme, K.....	551
Febrile Spontaneous Abortion and the IUD Kim-Farley, R.J., Cates, W., Jr., Ory, H.W. and Hatcher, R.A.....	561
Immunogenicity of Hapten-Protein Conjugates in Rabbits and Monkeys Preimmunized Against the Carrier Protein Sundaram, K. and Connell, K.G.....	571
Nurse Specialists in Family Planning: The Results of a 3-Year Study Newton, J., Barnes, G., Cameron, J. and Newton, P.....	577
Radioimmunoassay of Norethindrone: Serum Levels of Norethindrone in Lactating Women After Insertion of a Single Silastic Implant Releasing Norethindrone Acetate Laumas, V., Malik, B.K., Jamal, K., Seth, U., Agarwal, N., Hingorani, V. and Laumas, K.R.....	593
Clinical Trial With Testosterone Undecanoate for Male Fertility Control Nieschlag, E., Hoogen, H., Bölk, M., Schuster, H. and Wickings, E.J.....	607
A Radioimmunoassay for Norethindrone (NET): Measurement of Serum NET Concentrations Following Ingestion of NET-Containing Oral Contraceptive Steroids Stanczyk, F.Z., Brenner, P.F., Mishell, D.R., Jr., Ortiz, A., Gentzschein, E.K.E. and Goebelsmann, U.....	615
Termination of Second Trimester Pregnancy With Intraamniotic Administration of 16-Phenoxy-ω-Tetranor-PGE ₂ -Methyl sulfonamide (SHB 286) Alone and Combined With Oxytocin and Calcium Gluconate van den Bergh, A.S. and Haspels, A.A.....	635
Use of Intra- and Extra-Amniotic Prostaglandins for the Termination of Pregnancies: Report of Multicentric Trial in India Tejuja, S., Choudhury, S.D. and Manchanda, P.K.....	641
Announcement.....	653
Author Index for Volume 18.....	655
Subject Index for Volume 18.....	659

